首页 > 市场调查报告书 > 製药

孤儿药

拉丁美洲法布里病市场：按治疗类型（酵素替代疗法,伴侣疗法,底物还原疗法）,给药途径,分销渠道,国家-市场规模,份额,前景和机会分析2022-2030

市场调查报告书

商品编码

1149800

拉丁美洲法布里病市场：按治疗类型（酵素替代疗法,伴侣疗法,底物还原疗法）,给药途径,分销渠道,国家-市场规模,份额,前景和机会分析2022-2030

LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy Chaperon Therapy, Substrate Reduction Therapy ), by Route of Administration, by Distribution Channel, and by Country - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年09月26日 | 出版商:

Coherent Market Insights | 英文 245 Pages | 商品交期: 2-3个工作天内

价格

简介目录

法布里病是一种遗传性疾病，由体内细胞中堆积的三糖神经□胺（一种脂肪）引起。法布里病的症状可以出现在身体的任何部位，包括出汗能力下降、手脚酸痛和消化问题。脱氧核糖核酸序列分析和酵素分析等测试用于诊断法布里病。

法布里病的治疗方法包括静脉内酵素替代疗法和口服伴侣疗法，这可能还需要改变生活方式和进行预防性药物治疗。他们可能还会向您推荐止痛药、胃病药、治疗心律失常等心臟问题的血液稀释剂、降压药和保护肾臟的药。如果法布里病导致严重的肾臟损害，则可能需要透析或肾移植治疗。

市场动态

有关法布里病的结果和知识的研究有望推动拉美法布里病市场的增长。例如，根据 Orphanet Journal of Rare Diseases 于 2022 年 6 月 20 日发布的数据，一组研究人员将更好地了解法布里病，包括了解见解、结果，以及对其发展、治疗效果和治疗效果的了解更多。我们进行了一项为期 20 年的 Fabry 绩效研究，重点是深化。

监管机构更新了用于治疗法布里病的药物开髮指南，预计将推动拉丁美洲法布里病市场的增长。例如，2019 年 8 月，美国食品和药物管理局宣布提供工业界开发治疗法布里病药物的指南草案。本指南草案描述了 FDA 目前关于资格标准、研究设计注意事项和疗效终点的建议，这些建议将用于治疗法布里病的研究药物的临床开发计划。

这项研究的主要特点

本报告对拉丁美洲法布里病市场进行了深入分析，提供了以 2021 年为基准年的预测期（2022-2030 年）的市场规模（百万美元）和復合年增长率 (CAGR%)
它揭示了不同细分市场的潜在收入机会，并为该市场概述了一个有吸引力的投资建议矩阵。
它还提供了有关市场驱动因素和推动因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
根据公司概况、业绩、产品组合、市场占有率、分销战略、关键发展、战略和未来计划等参数对拉丁美洲法布里疾病市场的主要参与者进行了介绍。
本次调查涵盖的主要公司包括 Amicus Therapeutics, Inc.、Sanofi-Aventis U.S. LLC、GlaxoSmithKline plc、Mendelics、Takeda Pharmaceuticals U.S.A., Inc、Teva pharmaceutical Industries Ltd、Pfizer Inc.、Novartis AG、Moderna Therapeutics Inc 和Resverlogix。
这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
LATAM Fabry Disease 市场报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析 LATAM Fabry 疾病市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

报告内容
- 市场定义和范围
执行摘要
- 市场细分：按治疗类型
- 按给药途径细分的市场
- 市场细分：按分销渠道
- 按国家/地区划分的市场细分
连贯机会图 (COM)

第3章市场动态、规律及趋势分析

市场动态
- 司机
- 约束因素
- 市场机会
影响分析
市场趋势
主要发展状况
最近的产品发布/批准
市场参与者采用的主要策略
害虫分析
流行病学
併购

第 4 章 LATAM Fabry 市场：冠状病毒 (COVID-19) 大流行的影响

经济影响
对供应链的影响
政府举措

第 5 章拉丁美洲法布里病市场：按治疗类型分类，2017-2030

酵素替代疗法
2017-2030 年市场规模、预测、同比增长率
伴侣疗法
2017-2030 年市场规模、预测、同比增长率
酵素替代疗法
2017-2030 年市场规模和预测，同比增长率

第 6 章拉丁美洲法布里病市场：按给药途径，2017-2030

口服剂
肠外给药

第 7 章。拉丁美洲法布里病市场：分销渠道，2017-2030

医院药房
在线药店
零售药房

第 8 章拉丁美洲法布里病市场：国家，2017-2030

拉丁美洲
2017-2030 年按治疗类型划分的市场规模和预测
市场规模和预测：按给药途径，2017-2030 年
市场规模和预测：按分销渠道分类，2017-2030 年
按治疗类型划分的市场规模和预测：2017-2030 年
2017-2030 年按给药途径划分的市场规模和预测
2017-2030 年各分销渠道的市场规模和预测
2017 年至 2030 年按治疗类型划分的市场规模和预测
2017-2030 年按给药途径划分的市场规模和预测
2017-2030 年各分销渠道的市场规模和预测
2017 年至 2030 年按治疗类型划分的市场规模和预测
2017-2030 年按给药途径划分的市场规模和预测
市场规模和预测：按分销渠道分类，2017-2030 年

第9章竞争格局

热图分析
市场份额分析
- Amicus Therapeutics, Inc.
- Sanofi-Aventis U.S. LLC
- GlaxoSmithKline plc
- Mendelics
- Takeda Pharmaceuticals U.S.A., Inc.
- Teva pharmaceutical Industries Ltd
- Pfizer Inc.
- Novartis AG
- Moderna Therapeutics Inc
- Resverlogix

第 10 章

参考资料
调查方法介绍

简介目录

Product Code: CMI5249

Fabry disease is an inherited disorder which is caused by accumulation for globotriaosylceramide, a type of fat, in the body's cells. Fabry disease symptoms affect body parts which include a decreased ability to sweat, events of pain in hands and feet, difficulties with the gastrointestinal system, etc. Diagnosis for fabry disease includes test such as Deoxyribonucleic acid sequence analysis, enzyme assay analysis, etc.

Treatment for fabry disease includes intravenously administered enzyme replacement therapy or oral chaperone therapy, along with this it may also need lifestyle modifications and prophylactic medications. Sometimes doctors also refer drugs to relieve pain, medicine for stomach problems, blood thinners or other drugs for an irregular heartbeat or other heart problems, blood pressure medicine, which also helps to protect kidneys. If fabry disease has caused serious kidney damage, dialysis or a kidney transplant is needed for treatment.

Market Dynamics

Survey regarding achievements or learning about fabry disease, is expected to drive growth of the LATAM fabry disease market. For instance, according to data published on June 20, 2022, by Orphanet Journal of Rare Diseases, a team of researchers had done 20 years of Fabry Outcome Survey that focused to broaden the understanding of fabry disease such as to know about the insights, achievements, and learning more about the development of fabry disease, effects of treatment, etc. according to same Route of Administration population suffering from fabry disease has reported cardiovascular problem and it was more common type of problem reported in male and female in with fabry disease in Latin America.

Updated guidelines by regulatory bodies for the development of drugs used in the treatment of fabry disease is expected to drive the LATAM fabry disease market growth. For instance, in August, 2019, the U.S. Food and Drug Administration announced the availability the draft guidance for the industries, to develop drugs for the treatment of fabry disease. This draft guidance describes the FDA's current recommendations regarding eligibility criteria, trial design considerations, and efficacy endpoints to be used in clinical development programs of investigational drugs to treat fabry disease.

Key features of the study:

This report provides in-depth analysis of the LATAM fabry disease market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the LATAM fabry disease market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Amicus Therapeutics, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Mendelics, Takeda Pharmaceuticals U.S.A., Inc, Teva pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, Moderna Therapeutics Inc, and Resverlogix.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The LATAM fabry disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the LATAM fabry disease market

Detailed Segmentation:

LATAM Fabry Disease Market, By Therapy Type:
- Enzyme Replacement Therapy
  - Agalsidase Beta (Fabrazyme)
  - Agalsidase Alfa (Replagal)
  - Pegunigalsidase Alfa (PRX-102, Phase III)
- Chaperon Therapy
  - Migalastat (Galafold Phase III)
- Substrate Reduction Therapy
  - Lucerastat (Phase III)
  - Venglustat (Phase III)
LATAM Fabry Disease Market, By Route of Administration:
- Oral
- Parental
LATAM fabry disease market, By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
LATAM Fabry Disease Market, By Country:
- Brazil
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Mexico
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Argentina
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
- Rest of Latin America
  - By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online pharmacies
Company Profiles
- Amicus Therapeutics, Inc. *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Sanofi-Aventis U.S. LLC
- GlaxoSmithKline plc
- Mendelics
- Takeda Pharmaceuticals U.S.A., Inc.
- Teva pharmaceutical Industries Ltd
- Pfizer Inc.,
- Novartis AG
- Moderna Therapeutics Inc
- Resverlogix

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Country
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Recent Product Launch/Approval
Key Strategies Adopted by Market Players
PEST Analysis
Epidemiology
Mergers and Acquisitions

4. LATAM Fabry Disease Market - Impact of Coronavirus (COVID-19) Pandemic

Economic Impact
Impact on Supply Chain
Government Initiatives

5. LATAM Fabry Disease Market, By Therapy Type, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Enzyme Replacement Therapy
- Agalsidase Beta (Fabrazyme)
- Agalsidase Alfa (Replagal)
- Pegunigalsidase Alfa (PRX-102, Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Chaperon Therapy
- Migalastat (Galafold Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Enzyme Replacement Therapy
- Lucerastat (Phase III)
- Venglustat (Phase III)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. LATAM Fabry Disease Market, By Route of Administration, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. LATAM Fabry Disease Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. LATAM Fabry Disease Market, By Country, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Country, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Country, 2017-2030
Latin America
- Brazil
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Mexico
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Argentina
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Rest of Latin America
Market Size and Forecast, By Therapy Type, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2017 - 2030, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)